Why the Right Cell Type Matters More Than the Right Signal

Hatched by Miyabi

Jun 16, 2026

10 min read

2 views

87%

The hidden mistake in medicine: confusing the messenger with the target

What if a therapy fails not because the molecule is wrong, but because it lands in the wrong place inside the tissue? That question sounds almost too simple, yet it sits at the center of some of the most difficult problems in neurobiology and gene therapy. In one case, researchers map the retinal response wave by wave, showing that the b-wave is not just a generic electrical blip but a composite expression of specific cell types and their interactions. In another, a brain-directed gene therapy looks modest when driven by one promoter, then becomes meaningfully therapeutic when the same genetic cargo is expressed with a different cell-specific promoter. The lesson is unsettling and powerful: biology is not only about what signal you send, but about which cells are allowed to speak.

That is the deeper connection between retinal electrophysiology and viral gene delivery. Both reveal a world in which a measurable output is only the surface of a layered circuit. If you only stare at the output, you may miss the architecture underneath. And if you ignore the architecture, you may mistake partial rescue for failure, or failure for proof that the idea itself is flawed.

A waveform is not a single event, it is a negotiated compromise

The electroretinogram is often treated as a clean readout, a neat chart of retinal function. But the familiar a-wave, b-wave, and c-wave are not interchangeable markers of one process. They are layered expressions of different cell populations, different inputs, and different kinds of handoffs. The wave is less like a beep from a smoke detector and more like a conversation in a crowded room, where one group begins the exchange, another amplifies it, and another shapes the final contour.

That matters because it changes the question from “Is the retina responding?” to “Which part of the retinal network is responding, and in what way?” A waveform can look broadly intact while one critical cellular contributor is already failing. Conversely, a small change in the wave can reflect a disproportionately large functional improvement in the relevant cell layer. The visible signal is real, but it is never self-explanatory.

This is the first conceptual bridge to gene therapy. A therapy can deliver the correct gene, yet still fail if the expression pattern ignores the tissue logic. A promoter like CAG may be broadly active, but broad activity is not always biologically appropriate. When hSYN drives expression in neurons and produces stronger rescue, that is not merely a technical detail. It suggests that the disease is not just a missing protein problem. It is a cell identity problem.

A signal is only therapeutic when it reaches the cell that can convert it into the right downstream action.

The retinal waveform teaches the same principle in a different language. The output is an aggregate, but the disease may live in a subcomponent. Treating the whole graph as a single number is convenient, but biology rarely pays attention to our convenience.

Why broad expression can be weaker than precise expression

At first glance, broad promoters seem safer. If a gene is expressed in more cells, shouldn’t that increase the odds of rescue? In engineering terms, wider coverage should create redundancy. Yet biology is not an electrical grid, and tissues are not passive circuits. Cells differ not only in whether they can express a gene, but in how they process that gene, what partners they need, and what consequences follow from misexpression.

This helps explain why CAG can underperform while hSYN performs better in a neurodegenerative context. A generic promoter may produce protein in cells that do not need it, do not localize it correctly, or fail to integrate it into the right signaling context. Meanwhile, a neuron-biased promoter can concentrate expression where the disease mechanism actually unfolds. The goal is not maximal expression everywhere. The goal is effective expression in the right biological neighborhood.

Think of it like repairing a city’s power outage. Rewiring every building in town is expensive and noisy, but not always useful. If the failure is in a substation feeding the hospital district, the correct move is not to flood the whole city with electricity. It is to restore the substation. The same logic applies to neurobiology. A protein may be necessary in the nervous system, but only certain neurons may be able to turn it into a meaningful functional rescue.

There is a deeper caution here. The apparent universality of a promoter can create an illusion of completeness. But completeness is not the same as correctness. In complex tissues, where a gene is expressed may matter more than how much is expressed. Too much signal in the wrong cell can create noise, buffer the effect, or even trigger compensatory responses that dilute the benefit.

This is one reason gene therapy is increasingly becoming a question of cellular syntax. The same genetic sentence can mean something different depending on who is allowed to read it. A neuron, an astrocyte, a glial cell, and a photoreceptor do not merely differ in location. They differ in grammar, context, and downstream consequences.

The real unit of therapy is not the gene, but the circuit

A useful way to connect these ideas is to think in terms of functional circuits rather than isolated cells. The retina is a beautiful example of this because its output waves emerge from sequential processing. One cell type does not merely generate a signal in isolation. It hands off, modulates, and shapes what comes next. Likewise, the success of AAV-mediated CLN5 delivery depends not only on whether neurons make the protein, but on whether the broader circuit can recover enough integrity to normalize degeneration and biomarker readouts.

This suggests a broader thesis: disease is often a breakdown in information flow, and therapy succeeds when it restores the correct node in the flow, not merely the missing molecule.

That framing changes how we interpret biomarkers. A biomarker like a plasma indicator of neurodegeneration is valuable because it offers a view into hidden tissue damage, but it is still downstream of multiple biological decisions. If therapy normalizes the biomarker, that is encouraging. Yet the biomarker alone does not tell us whether rescue happened through neuronal survival, improved synaptic communication, altered inflammatory tone, or partial preservation of a vulnerable circuit. The marker is a shadow, not the object.

Similarly, the ERG waveform is a shadow of retinal computation. The a-wave, b-wave, and c-wave are not the retina itself. They are the trace left by cell populations doing work in sequence. Treating those traces as mere numbers risks flattening biology into bookkeeping. But if we read them as circuit signatures, they become maps.

The most important question is rarely “Did the molecule arrive?” It is “Did the circuit know what to do with it?”

This distinction matters across medicine. In neurodegeneration, restoring a protein to nonessential cells may improve a lab assay without changing the disease trajectory. In sensory systems, rescuing one wave may not repair another if the upstream and downstream layers remain compromised. In both cases, the difference between a plausible intervention and a real one lies in circuit logic.

A practical framework: expression, context, conversion

A simple framework can help make this idea usable beyond these specific examples. Every therapy that depends on tissue biology must clear three gates: expression, context, and conversion.

1. Expression: Is the intervention present where it needs to be?

This is the most obvious gate. The therapy has to get to the target tissue and be produced at sufficient levels. But expression alone is not enough, because abundant presence is not the same as functional presence.

2. Context: Is it being expressed in the right cell type and environment?

A promoter is not just a switch. It is a filter for context. CAG may drive expression broadly, but broad is not necessarily wise when the disease mechanism is concentrated in neurons. hSYN may work better precisely because it narrows the context to a biologically relevant population.

3. Conversion: Can the target cell turn the intervention into useful function?

A cell can receive a gene and still fail to convert it into meaningful rescue if it lacks the right partners, signaling milieu, or circuit position. In the retina, the b-wave reflects conversion across a layer of cells that amplify and shape the initial input. In neurodegeneration, the therapeutic protein must be converted into improved survival, reduced degeneration, or restored cellular homeostasis.

This framework is useful because it exposes a common error in translational thinking: assuming that biological delivery is equivalent to biological effect. It is not. Delivery is only the first step in a chain of conversion events.

A second, subtler benefit of the framework is that it encourages humility in interpreting failures. A weak result does not necessarily mean the molecule is ineffective. It may mean the expression context is wrong, or the intended cells cannot convert the signal efficiently. That is a much more actionable failure than a vague “the therapy did not work.”

Why this matters for the future of neuroscience and gene therapy

The most exciting frontier in these fields is not simply more powerful tools. It is more precise biological reasoning. We are moving from a phase of asking whether a tool can alter tissue to asking whether it can do so in a way the tissue can actually use.

That shift has consequences. It pushes gene therapy design toward cell type aware promoters, better delivery maps, and disease models that distinguish between rescue of one circuit element and rescue of the whole network. It also pushes functional assays, like electrophysiology and biomarkers, to be interpreted as layered outputs rather than single verdicts.

Imagine two therapies that both lower a biomarker. One does so by broadly increasing expression, but with modest functional benefit. The other does so by targeting the most relevant neurons, producing meaningful circuit recovery and long-term improvement. If we only rewarded the biomarker, we might choose the wrong one. If we only rewarded expression level, we might miss the fact that the tissue cares about specificity more than saturation.

This is where the retinal and gene therapy stories meet most profoundly. The retina reminds us that function is distributed across identifiable layers. Gene therapy reminds us that successful rescue depends on respecting those layers. Together they argue for a more mature view of intervention: not just correct the deficit, but enter the circuit at the right node.

Key Takeaways

Stop treating outputs as if they explain themselves. Whether it is an ERG waveform or a plasma biomarker, an observed signal is a composite of underlying cellular events.
Precision can outperform breadth. Broad gene expression is not inherently better than cell type restricted expression. The right promoter may matter more than maximal coverage.
Think in circuits, not molecules. Many diseases are failures of information flow across tissue architecture, so rescue must restore the relevant node in that flow.
Use a three part test for any therapy: expression, context, conversion. Ask not only whether the intervention arrives, but whether the right cells receive it and can turn it into meaningful function.
Interpret biomarkers as shadows, not verdicts. They are invaluable, but they do not replace mechanistic understanding of which cells and pathways have been restored.

The deeper lesson: biology rewards relevance, not abundance

It is tempting to believe that more signal automatically means more healing. More protein, more expression, more reach, more effect. But the connective tissue between these examples points to a different rule: biology rewards relevance. A signal becomes therapeutic only when it is delivered to the cell that can use it, in the context that permits it, within the circuit that needs it.

That is why a retinal waveform can teach us about gene therapy, and why gene therapy can teach us how to read a waveform. Both are reminders that life is not a flat map of inputs and outputs. It is a layered negotiation among cells, each with its own role in making a whole system function.

The next time a therapy appears weak, or a biomarker appears improved, the most important question may not be whether the signal was strong enough. It may be whether it was spoken in the right cellular dialect. That is where real rescue begins.